|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
11/1/2012 8:28:41 AM
SANTA ANA, Calif.--(BUSINESS WIRE)--Irvine Scientific, a leading cell culture media/ medical device company for more than 40 years, announced their newly launched cell therapy PRIME-XV™ product portfolio as part of the company’s commitment to accelerate basic research and clinical applications in cell therapy and regenerative medicine. Using their expertise in cell culture media development, PRIME-XV™ products were designed to function as part of an integrated workflow solution in culturing primary cells, where all products have been pre-validated to decrease end user qualification time. Initially, PRIME-XV™ products will comprise of a serum-free medium for the expansion of human mesenchymal stromal/ stem cells (MSCs), biopreservation solutions and extracellular matrix proteins. However, Irvine Scientific intends to expand this product line to offer other cell culture media and reagents, such as stem cell qualified fetal bovine serum, tumorsphere and neural progenitor cell expansion media. Examples of existing PRIME-XV™ products include:
|
|
|
|
|
|
|
|
|
|
|